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MaBACKGROUND Accurate assignment of statin therapy is a major public health issue.
OBJECTIVES The American Heart Association and the American College of Cardiology released a new guideline on
the assessment of cardiovascular risk (GACR) to replace the 2001 National Cholesterol Education Program (NCEP) Adult
Treatment Panel III recommendations. The aim of this study was to determine which method more accurately assigns
statins to patients with features of coronary imaging known to have predictive value for cardiovascular events and
whether more patients would be assigned to statins under the new method.
METHODS The burden of coronary atherosclerosis on computed tomography angiography was measured in several
ways on the basis of a 16-segment model. Whether to assign a given patient to statin therapy was compared between
the NCEP and GACR guidelines.
RESULTS A total of 3,076 subjects were studied (65.3% men, mean age 55.4  10.3 years, mean age of women
58.9  10.3 years). The probability of prescribing statins rose sharply with increasing plaque burden under the GACR
compared with the NCEP guideline. Under the NCEP guideline, 59% of patients with $50% stenosis of the left main
coronary artery and 40% of patients with $50% stenosis of other branches would not have been treated. The com-
parable results for the GACR were 19% and 10%. The use of low-density lipoprotein targets seriously degraded the
accuracy of the NCEP guideline for statin assignment. The proportion of patients assigned to statin therapy was 15%
higher under the GACR.
CONCLUSIONS The new American Heart Association/American College of Cardiology guideline matches statin
assignment to total plaque burden better than the older guidelines, with only a modest increase in the number
of patients who were assigned statins. (J Am Coll Cardiol 2014;64:910–9) © 2014 by the American College of
Cardiology Foundation.I n November 2013, the American Heart Associa-tion (AHA) and the American College of Cardiol-ogy (ACC) jointly published the guideline on the
assessment of cardiovascular risk (GACR) (1,2) to
replace the National Cholesterol Education Program
(NCEP) Adult Treatment Panel (ATP) III recommenda-
tions, released in 2001 (3). Some have suggested that
the new guideline overestimates risk and will result
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AB BR E V I A T I O N S
AND ACRONYM S
ACC = American College of
Cardiology
AHA = American Heart
Association
ASCVD = atherosclerotic
cardiovascular disease
ATP = Adult Treatment Panel
CHD = coronary heart disease
CI = conﬁdence interval
CTA = computed tomographic
angiography
GACR = AHA/ACC 2013
guideline on the assessment of
cardiovascular risk
LAD = left anterior descending
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911structured this analysis around these speciﬁc
questions:
1. Which method is more accurate in assigning
treatment to patients with features of coronary
imaging known to have predictive value for car-
diovascular events?
2. What accounts for the difference in performance of
the methods, if any?
3. Does the proportion of patients on statins differ
between the methods?
Our premise is that more plaque, especially more prox-
imal and stenotic plaque, means more risk. In particular,
we were interested in the extremes: How frequently are
patients with very heavy atherosclerotic burden not
assigned statins? Are many patients with no plaque
assigned statins?SEE PAGE 920
coronary artery
LDL = low-density lipoprotein
NCEP = National Cholesterol
Education Program
SIS = segmental involvement
score
SPS = segmental plaque
burden score
= segmental stenosis scoreMETHODS
STUDY POPULATION. The computed tomographic
angiograms of consecutive patients obtained at a
private outpatient radiology practice were reviewed.
Patients had presented for various reasons,
including stable atypical chest pain, indeterminate
stress test results, multiple risk factors, and a strong
family history. Risk factors and patient histories
were retrospectively collated from patient intake
forms and medical records. Patients were included
if they were 21 to 90 years of age and had readily
available lipid data. Patients younger than 40 years
or older than 75 years, without known atheroscle-
rotic cardiovascular disease (ASCVD) or low-density
lipoprotein (LDL) cholesterol $190 mg/dl, were not
included in further analyses, because the GACR
makes no recommendations for such patients. The
study complied with Health Insurance Portability
and Accountability Act guidelines and received a
waiver from the local institutional review board.
BASELINE CHOLESTEROL ESTIMATION. The NCEP
and GACR regression equations for risk estimation
were developed using data from a time when few
patients were on statins, and they do not speciﬁcally
account for statin use. In the present study, the
baseline total cholesterol and LDL cholesterol values
of patients on statins at the time of imaging were
estimated from the measured values. In one large
study, the average decrease in LDL cholesterol with
statin therapy was 34% and that of total cholesterol
25% (4). For patients on statins, this corresponds to
increasing the measured values of LDL cholesterol by
52% and total cholesterol by 33%. Analyses wererepeated in the subgroup of patients not on
statins at the time of imaging to conﬁrm
conclusions based on all patients. In addi-
tion, a sensitivity analysis was performed by
varying the LDL decrease between 10% and
70% with a proportional change in total
cholesterol level.
NCEP RISK ESTIMATION. Using the NCEP
ATP III panel recommendations, the percent
risk for coronary heart disease (CHD) at 10
years was calculated under its modiﬁed Fra-
mingham model (3). Then, risk factors were
assessed: smoking (any in the past month),
hypertension (history of hypertension or
systolic pressure $140 mm Hg), high-density
lipoprotein (counted as 1 if <40 mg/dl and
as 1 if >60 mg/dl), age (men, $45 years;
women, $55 years), and family history of
premature CHD in a ﬁrst-degree relative
(men, <55 years; women, <65 years). Patients
were categorized as low risk (0 or 1 risk fac-
tor), intermediate risk ($2 risk factors
and <10% risk for CHD at 10 years), moder-
ately high risk ($2 risk factors and 10% to
20% risk for CHD in 10 years), or high risk ($2
risk factors and >20% risk for CHD in 10 years). Pa-
tients with known CHD, diabetes, or peripheral
atherosclerosis were classiﬁed as high risk regardless
of their risk factor count or Framingham estimate.
The decision to start statins was based on an
LDL cholesterol target keyed to the risk category:
low risk, <160 mg/dl; intermediate risk, <130 mg/dl;
moderately high risk, <100 mg/dl; and high risk,
<70 mg/dl.
GACR RISK ESTIMATION. Under the GACR, 4 groups
beneﬁt from statins (2):
1. Known ASCVD with no New York Heart Association
functional class II to IV heart failure or dialysis
2. LDL cholesterol $190 mg/dl
3. Age 40 to 75 years with diabetes and LDL >70
and <190 mg/dl without ASCVD
4. Age 40 to 75 without ASCVD or diabetes, LDL >70
and <190 mg/dl, and estimated 10-year risk of 7.5%
or higher using new pooled cohort equations
Statins were assigned if a patient met any of these
criteria. The heart failure and dialysis exclusions were
not applied, because these data were unavailable.
CTA. Patients not already on beta-blockers received
100 mg of metoprolol by mouth about 1 h before
CTA. If the heart rate remained higher than 72
beats/min, an additional 50 to 100 mg was admin-
istered. Heart rate, electrocardiogram, and blood
SSS
TABLE 1 Patient Characteristics
Group
Not on Statins* at
Time of Imaging
On Statins* at
Time of Imaging
All
Patients
Men
n 870 (43.3) 1,140 (56.7) 2,010
Age, yrs 51.9  9.3 58.1  10.3 55.4  10.3
NCEP Framingham 10-yr risk, % 6 (3–10) 12 (6–20) 10 (5–16)
GACR 10-yr risk, % 4.7 (2.4–9.4) 11.3 (5.6–21.7) 7.4 (3.6–16.1)
NCEP core risk: low/intermediate/
moderately high/high
351 (40)/210 (24)/
154 (18)/155 (18)
194 (17)/113 (10)/
227 (20)/606 (53)
545 (27)/323 (16)/
381 (19)/761 (38)
BMI, kg/m2 28.9  4.1 29.4  4.3 29.2  4.2
Hypertension 466 (53.6) 832 (73.0) 1,298 (64.6)
Smoking in past month 112 (12.9) 165 (14.5) 277 (13.8)
First-degree relative with premature CHD
(men <55 yrs or women <65 yrs)
218 (25.1) 310 (27.2) 528 (26.3)
Diabetes 57 (6.6) 240 (21.1) 297 (14.8)
Known coronary disease 60 (6.9) 350 (30.7) 410 (20.4)
Known noncoronary atherosclerotic disease 21 (2.4) 89 (7.8) 110 (5.5)
Total cholesterol, mg/dl 204.2  39.4 184.9  49.4 194.1  46.0
LDL cholesterol, mg/dl 127.5  32.5 106.2  39.3 116.2  37.8
HDL cholesterol, mg/dl 48.8  13.1 47.4  15.2 48.1  14.2
Triglyceride, mg/dl 115 (80–175) 129 (93–185) 122 (86–179)
Women
n 492 (46.2) 574 (53.8) 1,066
Age, yrs 55.7  9.3 61.7  10.4 58.9  10.3
NCEP Framingham 10-yr risk, % 2 (1–4) 4 (2–8) 3 (1–6)
GACR 10-yr risk, % 2.9 (1.2–6.4) 6.7 (3.0–14.0) 4.4 (1.9–10.6)
NCEP core risk: low/intermediate/
moderately high/high
292 (59)/105 (21)/
14 (3)/81 (16)
175 (30)/120 (21)/
33 (6)/246 (43)
467 (44)/225 (21)/
47 (4)/327 (31)
BMI, kg/m2 27.7  5.4 28.5  5.3 28.1  5.4
Hypertension 249 (50.6) 429 (74.7) 678 (63.6)
Smoking in past month 89 (18.1) 84 (14.7) 173 (16.2)
First-degree relative with premature CHD
(men <55 yrs or women <65 yrs)
141 (28.7) 204 (35.5) 345 (32.3)
Diabetes 33 (6.7) 108 (18.9) 141 (13.3)
Known coronary disease 22 (4.4) 114 (19.9) 136 (12.8)
Known noncoronary atherosclerotic disease 21 (4.3) 66 (11.5) 87 (8.2)
Total cholesterol, mg/dl 212.8  42.2 201.4  46.7 207.1  44.9
LDL cholesterol, mg/dl 127.4  36.4 116.0  40.0 121.6  38.7
HDL cholesterol, mg/dl 61.6  17.2 57.5  15.6 59.5  16.5
Triglyceride, mg/dl 100 (70–140) 120 (88–172) 109.5 (78–157)
Values are n (%), mean  SD, or median (interquartile range). *Or other lipid-lowering drugs.
BMI ¼ body mass index; CHD ¼ coronary heart disease; GACR ¼ guideline on the assessment of cardiovascular risk; HDL ¼ high-density lipoprotein; LDL ¼ low-density
lipoprotein; NCEP ¼ National Cholesterol Education Program.
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912pressure were monitored. Sublingual nitroglycerin
spray 1/150 g was given 1 min before image acquisi-
tion. A 64-slice computed tomographic scanner was
used (VCT 64, GE Healthcare, Waukesha, Wisconsin).
An initial bolus-timing single-slice scan using 20 ml
of contrast (iodine content 320 mg/ml) (Visipaque,
GE Healthcare) was followed by a 20-ml saline
bolus. Contrast injection of 80 ml at a ﬂow rate of
5 ml/s was followed by a saline chaser, 50 ml at a
ﬂow rate of 5 ml/s. Collimation was 0.625 mm,
rotation time 0.35 ms, scan pitch 0.16 to 0.24
depending on heart rate, ﬁeld of view 25 cm,reconstruction matrix 512  512, table feed 20 mm/
rotation, tube voltage 120 kVp, and tube current
450 to 800 mA. Electrocardiographic dose modula-
tion was used when possible. Electrocardiographi-
cally gated datasets were reconstructed from
70%, 75%, and 80% of the R-R cycle length; additional
reconstruction windows were used if motion arti-
facts were present. Cases after June 2006 mostly
used prospective gating, while the rest were retro-
spectively gated. Overall, approximately two-thirds of
the cases in this study were done with prospective
gating.
TABLE 2 Most Frequent Reasons for Coronary Computed
Tomographic Arteriography by Patient Report*
Hypercholesterolemia 1,907 (62.0)
Family history of heart disease 1,716 (55.8)
Hypertension 1,375 (44.7)
Smoking history 1,196 (38.9)
High triglycerides 554 (18.0)
Dyspnea on exertion 493 (16.0)
Chest pain unspeciﬁed 430 (14.0)
Diabetes 375 (12.2)
Chest pain not related to exertion 358 (11.6)
Abnormal/indeterminate stress test results 335 (10.9)
Chest pain on exertion 326 (10.6)
Left arm, upper back, jaw pain 292 (9.5)
Abnormal electrocardiographic results 275 (8.9)
Values are n (%). *Includes >1 reason per patient.
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913PLAQUE BURDEN AND STENOSES SCORING.
Methods of scoring plaque burden have been dis-
cussed in detail previously (5). The coronary tree was
analyzed using the AHA’s 1975 16-segment deﬁni-
tions (6). Cases with image quality designated as
“limited” for any reason were excluded. Heavy
calciﬁcation was not an exclusion criterion.
Each coronary examination was scored using the
following 3 methods:
1. Segmental plaque burden score (SPS): For each
segment, plaque amount was scored as none or
trace (0), mild (1), moderate (2), or heavy (3). These
refer to the volume of plaque within a segment,
whether calciﬁed or not. In the case of multiple
lesions, the score reﬂected the segment as a whole.
The SPS was calculated as the sum of the individ-
ual segment scores.
2. Segmental stenosis score (SSS): Same as above, but
using an estimate of worst diameter stenosis per
segment rather than plaque volume, scored as very
mild, <30% (0); mild, 30% to 49% (1); moderate,
50% to 69% (2); or severe, $70% (3). The SSS was
calculated as the sum of the individual segment
scores.TABLE 3 Correlation of 10-Year Risk Estimates With Plaque Measure
Plaque
Measure
All Patients
NCEP GACR
SPS 0.511 (0.482–0.539) 0.560 (0.533–0.58
SSS 0.466 (0.435–0.495) 0.520 (0.492–0.54
SIS 0.513 (0.484–0.541) 0.562 (0.535–0.58
Values are Spearman’s rho correlation coefﬁcient (95% conﬁdence interval). *Or other l
SIS ¼ segmental involvement score; SPS ¼ segmental plaque burden score; SSS ¼ se3. Segmental involvement score (SIS): For each
segment, plaque amount was scored as absent or
trace (0) or present (1), whether calciﬁed or not.
The SIS was calculated as the sum of the individual
segment scores.
In an earlier paper (5), we established reference
values for the plaque-scoring methods using data
from patients with known coronary artery disease.
For the SPS, the category cutoff values were 0 (zero),
1 to 3 (mild), 4 to 7 (moderate), and $8 (heavy). A
similar procedure was used to establish the values for
the SSS method (0, 1 to 3, 4 to 8, and $9) and the SIS
method (0, 1 or 2, 3 or 4, and >4).
SPS is an overall plaque burden score. However,
SSS and SIS are better established in the published
research. In particular, SSS is closely allied to the
Duke prognostic score. Other investigators have
shown outcome data for SIS and SSS (7,8) All 3 have
been included.
PROGNOSTIC FEATURES. Certain ﬁndings may
correlate with higher risk, in particular patterns of
more proximal disease (7). Two prognostic assess-
ments of this type were used:
1. Modiﬁed Duke prognostic index: This index,
derived from conventional angiographic data,
correlates with cardiac morbidity and mortality (9).
For each segment, stenosis is graded visually as
very mild (<30% diameter), mild (30% to 49%),
moderate (50% to 69%), or severe ($70%). Then
permutations of lesions carrying increasing risk
for a coronary event are deﬁned. The original
scheme used 16 combinations, but we adopt the
following modiﬁcation. The categories are 0, no or
trace plaque; 1, very mild or mild stenoses; 2, $2
mild stenoses with 1 proximal or 1 moderate ste-
nosis; 3, 2 moderate stenoses or 1 severe stenosis;
4, 3 moderate stenoses or 2 severe stenoses or
proximal left anterior descending coronary artery
(LAD) severe stenosis; 5, 3 severe stenoses or 2
severe stenoses with proximal LAD involved; and
6, moderate or severe left main stenosis.s
Patients Not on Statins* at Time of Imaging
NCEP GACR
6) 0.482 (0.438–0.523) 0.500 (0.458–0.540)
8) 0.452 (0.407–0.495) 0.487 (0.444–0.528)
7) 0.492 (0.449–0.533) 0.514 (0.472–0.553)
ipid-lowering drugs.
gmental stenosis score; other abbreviations as in Table 1.
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FIGURE 1 Probability of Assigning Statin Therapy
Logistic regression estimates the probability of assigning statin
therapy as a function of segmental plaque burden score (SPS), a
measure of total plaque burden (A), or segmental stenosis
score (SSS), a measure of stenoses presence and severity (B).
The newer guideline on the assessment of cardiovascular risk
(GACR) method substantially outperforms the older National
Cholesterol Education Program (NCEP) method (all patients).
Dotted line at SPS ¼ 8 or SSS ¼ 9 represents beginning of
“heavy” disease category. The y-axis is the probability of
being assigned statins; the x-axis is the measure of disease
burden, SPS or SSS.
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9142. Criteria emphasized in a meta-analysis of 11 prog-
nostic studies by Bamberg et al. (8): Left main
stenosis $50%, any stenosis $50%, and any
plaque. The number of proximal segments with
stenosis $50% was also assessed, deﬁned as
proximal right coronary artery, middle right coro-
nary artery, left main coronary artery, proximal
LAD, middle LAD, proximal circumﬂex coronary
artery, and obtuse marginal branch, following
Hadamitzky et al. (7).STATISTICAL ANALYSIS. Discrete variables are re-
ported as proportions and continuous variables as
mean  SD, if approximately normally distributed, or
as median (interquartile range) if not. Statistical
signiﬁcance was deﬁned at the #0.05 level for all
analyses (2-tailed). Spearman’s rho was used for
correlation because several important variables were
substantially skewed; 95% conﬁdence intervals (CI)
for rho were calculated using Fisher’s z trans-
formation. Logistic regression was used, with the
decision whether to start a statin as the dichotomous
variable and various measures of disease severity as
the continuous variable. Unit odds ratios with 95%
CIs were calculated. McNemar’s test was used to
estimate the signiﬁcance of the difference in pro-
portions of patients assigned to statin therapy by the
2 risk methods. JMP Pro version 10.0.0 (SAS Institute
Inc., Cary, North Carolina) was used to perform the
analysis.
RESULTS
POPULATION. Between February 2004 andNovember
2009, 3,346 patients met the inclusion criteria. Of the
cases, 270 (8.1 %) were judged as technically limited
and were excluded. The remaining 3,076 subjects
were studied (65.3% men, mean age 55.4  10.3
years, mean age of women 58.9  10.3 years, >90%
Caucasian) (Table 1). The median NCEP Framingham
10-year risk was 10% for men and 3% for women.
The most common reasons for undergoing CTA
were hypercholesterolemia, family history of CHD,
hypertension, smoking, and various kinds of non-
acute chest pain (Table 2).
At the time of imaging, 1,362 patients (44.3%) were
not on statins or other lipid-lowering therapy; the
remaining 1,714 patients (55.7%) were on statins.
Patients not on statins had less disease than patients
on statins: the 10th, 25th, 50th, 75th, 90th, and 97.5th
percentile scores for SPS were 0, 0, 1, 3, 6.7, and 12
and 0, 1, 3, 8, 12, and 18, respectively.
CORRELATION OF 10-YEAR RISK ESTIMATES WITH
PLAQUE. The newer risk estimation method (GACR)
was correlated marginally better with plaque and
stenosis burden than the older method (NCEP). For
all patients, the correlation of SPS with the NCEP
10-year risk estimate was 0.51 (95% CI: 0.48 to 0.54),
whereas with the GACR estimate, it was 0.56 (95% CI:
0.53 to 0.59) (Table 3).
PROBABILITY OF ASSIGNING STATINS. The proba-
bility of prescribing statins as a function of plaque
burden under each method is shown by the logistic
regression results in Figure 1. The probability curve
TABLE 4 Odds of Assigning Statin Therapy Under the GACR and
the NCEP Guideline
Variable
Unit Odds
Ratio
95% Conﬁdence
Interval Generalized R2
All patients
NCEP
SPS 1.02 1.00–1.03 0.002
SSS 1.02 1.01–1.04 0.005
SIS 1.06 1.04–1.09 0.010
Duke prognostic score 1.08 1.03–1.13 0.005
Proximal segments $50% 1.08 1.00–1.17 0.002
GACR
SPS 1.36 1.31–1.40 0.250
SSS 1.27 1.24–1.31 0.201
SIS 1.49 1.43–1.55 0.145
Duke prognostic score 1.85 1.72–2.00 0.175
Proximal segments $50% 3.14 2.63–3.82 0.125
Patients not on statins
at time of imaging
NCEP
SPS 1.10 1.07–1.14 0.039
SSS 1.07 1.05–1.10 0.031
SIS 1.19 1.14–1.25 0.054
Duke prognostic score 1.24 1.15–1.34 0.029
Proximal segments $50% 1.36 1.18–1.59 0.176
GACR
SPS 1.35 1.29–1.41 0.215
SSS 1.27 1.22–1.33 0.197
SIS 1.49 1.41–1.58 0.219
Duke prognostic score 1.70 1.54–1.88 0.140
Proximal segments $50% 2.56 2.05–3.29 0.100
The decision to start a statin on the basis of the NCEP guideline or the GACR is the dichotomous
variable, and various measures of disease severity are the continuous variables. In every case, the
GACR outperforms the NCEP guideline.
Abbreviations as in Tables 1 and 3.
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915rose sharply with increasing plaque burden. For the
corresponding odds ratios in Table 4, there is no
overlap of the 95% CIs; in all cases, the GACR per-
formed better than the NCEP guideline.
The GACR assigned fewer patients with no plaque
to statins and more patients with heavy plaque to
statins. Of patients with heavy plaque (SPS $ 8), 53%
would be assigned to statin therapy under the NCEP
guideline and 92% under the GACR. Of patients with
no or trace plaque, 41% would be assigned to statin
therapy under the NCEP guideline and 36% under the
GACR (Table 5). Of note, under the NCEP guideline,
59% of patients with $50% stenosis of the left main
coronary artery and 40% of patients with $50% ste-
nosis of other branches would not have been treated.
The comparable results for the GACR were 18% and
10%. As shown in Table 5, the NCEP guideline was
more likely to assign statins to patients with little
plaque and less likely to assign statins to those with
much plaque.
The sensitivity analysis for estimated baseline
cholesterol values did not alter our conclusions
(Figure 2).
DIFFERENT PERFORMANCE OF THE METHODS.
Patients with known atherosclerosis and diabetes are
considered high risk in both schemes. Removing LDL
cholesterol of 190 mg/dl or greater as a condition
(criterion 2) resulted in little change (data not
shown). Replacing the GACR 10-year risk equation
with the NCEP equation (criterion 4) also resulted in
little change (Figure 3).
Although the GACR and NCEP methods partition
patients into groups of similar kinds, the NCEP
method then applies LDL targets. However, the cor-
relations of serum LDL cholesterol levels with most
plaque measures are not signiﬁcantly different from
zero (Figure 4). This includes plaque features known
to correlate with risk and includes patients with LDL
of 190 mg/dl or greater.
We found that this lack of correlation largely
destroyed the discrimination achieved by the risk
categorization. To demonstrate this, we altered the
NCEP method by not applying the LDL targets.
Instead, all patients in NCEP categories 3 (moderately
high risk) and 4 (high risk) were assigned to statins,
and those in categories 1 and 2 were not. The per-
formance of this altered NCEP approach was similar
to the GACR (Central Illustration), representing a
substantial improvement.
PROPORTION OF PATIENTS ASSIGNED TO STATINS.
The proportion of patients assigned to statin therapy
under the NCEP guideline was 53%, compared with
61% under the GACR (all patients) (Table 6).DISCUSSION
Compared with the NCEP ATP III guideline, the GACR
better discriminates between patients with little or
no plaque and those with much plaque. Under the
new guidelines, the probability of being assigned
statin therapy better tracks the underlying plaque
and stenosis severity.
In this study, plaque burden is used as a surrogate
for cardiac events, which are the ultimate end point to
determine accuracy. This hypothesis is partially
proved in symptomatic patients but remains un-
proved in the primary prevention setting. Other
physiologic, as opposed to epidemiologic, factors also
contribute to risk, including the blood’s propensity
to clot and the vulnerability of plaque rupture. CTA
cannot assess the thrombogenicity of blood. In the
present study, we did not evaluate the radiodensity of
the plaque, which has been shown to correlate to some
TABLE 5 Proportions of Patients Assigned to Statin Therapy Given Various Plaque and
Prognostic Features
Disease Feature
All Patients
Patients Not on Statins at
Time of Imaging
n* NCEP GACR p Value n* NCEP GACR p Value
Any or none 3,076 0.531 0.608 <0.0001 1,362 0.376 0.357 0.18
SPS
Zero 954 0.411 0.359 0.0006 586 0.242 0.189 0.0056
Mild 991 0.600 0.568 0.051 471 0.444 0.348 0.0001
Moderate 584 0.608 0.789 <0.0001 193 0.549 0.617 0.13
Heavy 547 0.532 0.921 <0.0001 112 0.491 0.821 <0.0001
SSS
Zero 1,424 0.458 0.421 0.0048 809 0.282 0.221 0.0002
Mild 682 0.622 0.638 0.44 292 0.503 0.425 0.018
Moderate 497 0.576 0.809 <0.0001 155 0.510 0.632 0.017
Heavy 473 0.573 0.915 <0.0001 106 0.547 0.802 <0.0001
SIS
Zero 883 0.398 0.340 0.0003 552 0.241 0.178 0.0013
Mild 838 0.593 0.548 0.012 405 0.422 0.316 <0.0001
Moderate 540 0.594 0.732 <0.0001 204 0.505 0.539 0.35
Heavy 815 0.569 0.879 <0.0001 201 0.522 0.746 <0.0001
Duke prognostic score
Zero 1,427 0.459 0.423 0.0048 809 0.282 0.221 0.0002
1 917 0.603 0.678 <0.0001 367 0.510 0.488 0.48
2–4 466 0.618 0.876 <0.0001 115 0.565 0.661 0.086
5 or 6 266 0.515 0.891 <0.0001 71 0.451 0.732 0.0002
Left main stenosis $50%
No 3,054 0.532 0.606 <0.0001 1,356 0.376 0.356 0.16
Yes 22 0.410 0.818 0.0067 6 0.333 0.500 0.56
Any stenosis $50%
No 2,433 0.513 0.530 0.12 1,210 0.353 0.310 0.0037
Yes 643 0.597 0.902 <0.0001 152 0.559 0.730 0.0006
Any plaque
No 954 0.411 0.356 0.0006 586 0.242 0.189 0.0056
Yes 2,122 0.585 0.720 <0.0001 776 0.477 0.483 0.75
Proximal segments $50%
#2 2,913 0.527 0.588 <0.0001 1,317 0.369 0.339 0.035
>2 163 0.595 0.957 <0.0001 45 0.578 0.889 0.001
*Number of patients in each disease feature category; the proportion of that number assigned statin therapy
under either the NCEP or GACR guideline is shown in the other columns.
Abbreviations as in Tables 1 and 3.
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FIGURE 2 Sensitivity of Logistic Regression to
Assumed Reduction in Serum LDL
For those patients already on statins at the time of imaging,
the assumed percent reduction in serum low-density lipoprotein
(LDL) cholesterol level compared with pretreatment baseline
varied from 10% to 70%, in increments of 10%. The essential
difference in performance of the 2 risk methods is preserved
across the range of assumed cholesterol reduction. The lower
group of lines refers to National Cholesterol Education Program
(NCEP) and the upper group to the guideline on the assessment
of cardiovascular risk (GACR). The y-axis is the probability of
being assigned statins; the x-axis is segmental plaque burden
score (SPS), a measure of total plaque burden.
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FIGURE 3 Effect of Substituting Risk Equations
The probability of assigning statins is plotted versus the
segmental plaque burden score. When GACR criteria are applied
but the NCEP risk equation is used in the decision process instead
of the new GACR risk equation, the assignment results are almost
the same. Abbreviations as in Figure 2.
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916degree with vulnerability but with technical difﬁculty
because of limited spatial and contrast resolution.
There was not a signiﬁcant difference in the
correlation of the 10-year risk estimates with pla-
que or stenosis burden. Nonetheless, there was
a marked difference in the probability of being
assigned to statin therapy as a function of the un-
derlying plaque and prognostic measures. If accu-
racy is deﬁned as assigning statins to patients
with greater risk for disease, and not to those
without, the GACR outperformed the NCEP guide-
line substantially.
The use of LDL cholesterol targets by the NCEP
led to this difference. The GACR and NCEP methods
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FIGURE 4 Lack of Correlation Between Plaque Burden and
LDL Cholesterol
Scatterplot of segmental plaque burden score (SPS), a measure
of plaque burden, versus serum low-density lipoprotein (LDL)
cholesterol in patients with any plaque, not on statins at the time
of imaging. A density ellipse with alpha ¼ 0.99 is shown. The
correlation is not signiﬁcantly different from zero (0.016; 95%
conﬁdence interval: 0.055 to 0.086).
TABLE 6 Numbers of Patients Assigned to Statin Therapy Under
the NCEP Guideline and the GACR
Group All Patients
Patients Not on Statins
at Time of Imaging
NCEP guideline 1,633/3,076 (53.1%) 512/1,362 (37.6%)
GACR 1,870/3,076 (60.8%) 486/1,362 (35.7%)
Values are n/N (%).
Abbreviations as in Table 1.
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CENTRAL ILLUSTRATION Probability of Assigning Statin Therapy Versus
Plaque Burden Under 2 Cardiovascular Risk Guidelines
The y-axis is the probability of being assigned statins; the x-axis is segmental plaque
burden score (SPS), a measure of total plaque burden. Red is the Guideline on the
Assessment of Cardiovascular Risk (GACR) curve, green is the original National Cholesterol
Education Program (NCEP) curve. The GACR method does a much better job of assigning
statins to patients with high plaque burdens (SPS >8). Blue is the curve for the NCEP
method but without using low-density lipoprotein (LDL) cholesterol targets as the ﬁnal
step. It is quite similar to the GACR curve. Thus, most of the difference in statin assignment
between the new GACR guideline and the older NCEP guideline does not result from the
new risk equation but rather from having eliminated the step of using cholesterol targets.
J A C C V O L . 6 4 , N O . 9 , 2 0 1 4 Johnson and Dowe
S E P T E M B E R 2 , 2 0 1 4 : 9 1 0 – 9 Cholesterol Guidelines Versus Coronary Plaque Measures
917partition patients into risk groups in similar ways, but
the NCEP method then applies LDL targets to decide
who gets statin therapy. The correlation of serum
LDL cholesterol levels with various plaque measures
is not signiﬁcantly different from zero. This lack
of correlation largely destroys the discrimination
achieved by the risk categorization. The AHA/ACC
committee cited the lack of clinical trial data to
support its decision to no longer use targets (2). This
study reinforces this methodological decision, by
showing that these targets degrade the accuracy of
assignment of patients to statin therapy, in the
sense of correlation with underlying atherosclerosis
severity.
The proportion of patients on statins is modestly
larger under the GACR, about 15% more patients than
under the NCEP guideline (Table 6). This is in
approximate agreement with projections by others
(10). However, Ridker and Cook (11) showed over-
estimation of risk when the GACR is applied. If the
appropriate risk threshold desired is 7.5%, the nom-
inal threshold would need to be raised to compensate
for this overestimation, and the proportion of pa-
tients on statins would decrease. Ideally, such an
adjustment would be based on a comprehensive cost-
beneﬁt analysis.
There are still large numbers of patients with no
plaque being assigned to statin therapy under both
guidelines, but the GACR performed slightly betterthan did the NCEP guideline. The event risk in
patients with normal results on CTA is known to be
very low (8,12–14). At the same time, statins are
not without complications and expense (15). It
does not appear that these risk estimators can
distinguish patients with little or no disease from
those in whom it is clearly present. The simple
absence of calciﬁcation on coronary imaging
likely could substantially improve this discrimina-
tion in asymptomatic patients, at least in non-
diabetics (16).
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: A key
difference between the 2013 ACC/AHA guidelines for
the management of blood cholesterol and previous
recommendations under the NCEP involves the se-
lection of patients for statin therapy on the basis of an
overall assessment of cardiovascular risk rather than
LDL threshold criteria.
COMPETENCY IN PATIENT CARE: Following the
2013 ACC/AHA guidelines for the management of
blood cholesterol will likely assign more patients with
coronary disease to statin therapy and result in
treating approximately 15% more patients overall.
TRANSLATIONAL OUTLOOK: Because available
guidelines recommend treatment of a large number
of patients with relatively mild or no vascular dis-
ease, better methods are needed to identify low-risk
patients who could safely forgo statin therapy.
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918STUDY LIMITATIONS. For the patients already on
statins or other lipid-lowering medications at the
time of the imaging, the analysis estimated baseline
cholesterol values by increasing the measured value.
This added uncertainty to the results. For this
reason, the analyses were repeated in the subgroup
of patients not on statins at the time of imaging and
in those who did not require estimation of baseline
cholesterol values. The sensitivity analysis for esti-
mated baseline cholesterol values did not alter our
conclusions.
Heart failure and dialysis status were unknown
and thus could not be used with the GACR criteria.
Seriously ill patients did not account for many cases
in this nonacute outpatient setting. The inclusion of a
few patients of this type would not be expected to
materially change our results.
In this single-center retrospective study, the pop-
ulation was mostly Caucasian, from a single subur-
ban, smaller city area. Referral bias is a consideration;
the patients were referred mostly by primary care
physicians and cardiologists because of nonspeciﬁc
symptoms or indeterminate stress test results or
because of multiple risk factors. Nonetheless, this
patient spectrum can be expected to reﬂect the
population of patients likely to undergo CTA
outside an acute chest pain setting in predomi-
nantly white communities. Inclusion was biased
somewhat toward higher risk patients (Table 1). In
contrast, the population sent for such a study in
daily clinical settings is likely to be biased in a
similar way. As shown in Table 2, few patients had
symptoms, but many had risk factors. These are the
patients one might be most inclined to image if the
goal is to determine who in fact has a heavy plaque
burden and are therefore (presumably) at high risk
for events.
Risk factors were by patient report for the most
part. The laboratory data were a sample of conve-
nience in that manpower limitations allowed the
retrieval of laboratory data on only a subset of all
patients who had presented for CTA.
CONCLUSIONS
The 2013 guideline proposed by the AHA and the ACC
(2) results in a better discrimination of total plaque
and stenosis burden than does the 2001 NCEP ATP IIIguideline (3). On the basis of our ﬁndings, it is a
reasonable hypothesis that the new guideline will
better predict coronary events, given that it better
correlates with the severity of underlying athero-
sclerosis. Outcome studies are needed to conﬁrm this
hypothesis. The proportion of patients assigned
to statins under the new guideline is modestly
larger than under the older recommendations. The
GACR may overestimate risk, but after adjusting for
this, the proportion of patients assigned to statins
may not be much different than under the older
guideline.
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